Iterum Therapeutics Plc Financials
This page shows Iterum Therapeutics Plc (ITRMF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing still carries this development-stage balance sheet as management can throttle R&D faster than liabilities unwind.
From FY2023 to FY2024, operating loss shrank from-$47.5M to-$18.7M largely because R&D spending was cut, not because the company began funding itself. That is visible in cash: FY2024 operating cash flow was-$26.8M against year-end cash of$24.1M , so the balance sheet leaned on that year’s financing inflow rather than internally generated cash.
Cash burn matched accounting losses in FY2024, with net income of
Short-term liquidity looks better than the capital structure beneath it: the current ratio ended FY2024 at 1.4x, yet liabilities still exceeded assets by about
Financial Health Signals
Iterum Therapeutics Plc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Iterum Therapeutics Plc passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Iterum Therapeutics Plc reported a net loss of $24.8M while operations used $26.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Iterum Therapeutics Plc reported an operating loss of $18.7M against $3.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Iterum Therapeutics Plc's EBITDA was -$18.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 59.7% from the prior year.
Iterum Therapeutics Plc reported -$24.8M in net income in fiscal year 2024. This represents an increase of 35.4% from the prior year.
Iterum Therapeutics Plc earned -$1.26 per diluted share (EPS) in fiscal year 2024.
Not reported for fiscal year 2024.
Cash & Balance Sheet
Iterum Therapeutics Plc recorded an outflow of $26.8M in free cash flow in fiscal year 2024, representing a cash shortfall after capex. This represents an increase of 32.0% from the prior year.
Iterum Therapeutics Plc held $24.1M in cash against $31.2M in long-term debt as of fiscal year 2024.
Not reported for fiscal year 2024.
Margins & Returns
None of these metrics is reported for fiscal year 2024.
Capital Allocation
Iterum Therapeutics Plc invested $10.5M in research and development in fiscal year 2024. This represents a decrease of 73.8% from the prior year.
Iterum Therapeutics Plc invested $2K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 84.6% from the prior year.
Not reported for fiscal year 2024.
ITRMF Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $0 | $0-100.0% | $37K-95.7% | $869K+71.1% | $508K | $0 |
| R&D Expenses | N/A | $10.5M-73.8% | $40.0M+127.0% | $17.6M+64.5% | $10.7M-49.2% | $21.1M-76.8% | $90.8M+32.2% | $68.6M+169.2% | $25.5M+152.4% | $10.1M |
| SG&A Expenses | N/A | $8.0M+6.8% | $7.5M-41.4% | $12.8M-7.7% | $13.8M+25.1% | $11.1M-2.1% | $11.3M+28.5% | $8.8M+96.7% | $4.5M+37.0% | $3.3M |
| Operating Income | N/A | -$18.7M+60.6% | -$47.5M-56.2% | -$30.4M-23.8% | -$24.5M+23.6% | -$32.1M+68.5% | -$102.0M-33.3% | -$76.6M-159.9% | -$29.5M-120.5% | -$13.4M |
| Interest Expense | N/A | $3.3M+5.1% | $3.1M-0.9% | $3.2M | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | $240K-60.8% | $613K+103.7% | $301K-57.3% | $705K-5.1% | $743K+67.3% | $444K-5.9% | $472K+6.3% | $444K+292.9% | $113K |
| Net Income | N/A | -$24.8M+35.4% | -$38.4M+13.6% | -$44.4M+51.5% | -$91.6M-76.1% | -$52.0M+49.6% | -$103.1M-33.8% | -$77.1M-162.0% | -$29.4M-118.4% | -$13.5M |
| EPS (Diluted) | — | -$1.26 | -$2.96+18.5% | -$3.63+56.8% | -$8.41 | -$32.49 | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q4 FY2024 through Q3 FY2025, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ITRMF Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $44.6M+69.8% | $26.3M-60.7% | $66.8M-27.0% | $91.5M+179.1% | $32.8M+27.3% | $25.8M-73.7% | $97.9M+109.3% | $46.8M | N/A |
| Current Assets | $24.8M-3.2% | $25.6M-59.0% | $62.4M-25.0% | $83.3M+287.8% | $21.5M+83.2% | $11.7M-87.4% | $93.0M+110.5% | $44.2M | N/A |
| Cash & Equivalents | $24.1M+297.4% | $6.1M-71.2% | $21.1M-23.2% | $27.4M+89.2% | $14.5M+202.2% | $4.8M-89.2% | $44.6M+425.1% | $8.5M | N/A |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | N/A |
| Total Liabilities | $48.7M+49.0% | $32.7M-15.9% | $38.8M-5.9% | $41.3M-50.5% | $83.4M+60.3% | $52.0M+98.1% | $26.2M+264.3% | $7.2M | N/A |
| Current Liabilities | $17.6M+30.2% | $13.5M+49.1% | $9.1M-30.0% | $12.9M-69.0% | $41.7M+12.7% | $37.0M+202.7% | $12.2M+71.5% | $7.1M | N/A |
| Long-Term Debt | $31.2M+172.6% | $11.5M+13.5% | $10.1M+45.7% | $6.9M-69.1% | $22.5M+194.6% | $7.6M-41.7% | $13.1M | $0 | N/A |
| Total Equity | -$4.1M+36.3% | -$6.4M-122.9% | $28.0M-44.3% | $50.2M+199.4% | -$50.6M-92.7% | -$26.2M-136.6% | $71.6M+81.3% | $39.5M+74.2% | $22.7M |
| Retained Earnings | -$486.1M-5.4% | -$461.3M-9.1% | -$422.9M-11.7% | -$378.5M-31.9% | -$286.9M-22.1% | -$234.9M-78.3% | -$131.8M-140.8% | -$54.7M | N/A |
Not reported in any period shown, so not listed: Accounts Receivable, Goodwill.
ITRMF Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$19.5M | -$26.8M+31.9% | -$39.3M-112.9% | -$18.5M-16.6% | -$15.8M+70.9% | -$54.5M+33.4% | -$81.9M-6.0% | -$77.3M-152.4% | -$30.6M-170.9% | -$11.3M |
| Capital Expenditures | $14K | $2K-84.6% | $13K-79.0% | $62K+1.6% | $61K+454.5% | $11K-54.2% | $24K-73.3% | $90K-88.9% | $812K | N/A |
| Free Cash Flow | -$19.5M | -$26.8M+32.0% | -$39.3M-112.3% | -$18.5M-16.6% | -$15.9M+70.8% | -$54.5M+33.4% | -$81.9M-6.0% | -$77.3M-146.2% | -$31.4M | N/A |
| Investing Cash Flow | $1.1M | $18.2M-22.0% | $23.3M+67.2% | $14.0M+125.6% | -$54.6M-496218.2% | -$11K-100.0% | $40.1M+563.2% | -$8.7M+72.6% | -$31.6M | N/A |
| Financing Cash Flow | $16.0M | $26.7M+2481.3% | $1.0M+156.9% | -$1.8M-102.2% | $83.1M+28.9% | $64.5M+3025.3% | $2.1M-98.3% | $122.2M+166.4% | $45.9M+120.0% | $20.9M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q4 FY2024 through Q3 FY2025, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ITRMF Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | N/A | N/A | -275732.4% | -8810.0% | -5798.2% | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | -278729.7% | -8867.2% | -5788.6% | N/A |
| Return on Equity | N/A | N/A | -158.7%+23.6pp | -182.3% | N/A | N/A | -107.6%-33.1pp | -74.5%-15.1pp | -59.4% |
| Return on Assets | -55.5%+90.6pp | -146.1%-79.6pp | -66.5%+33.6pp | -100.1%+58.5pp | -158.6%+241.9pp | -400.5%-321.8pp | -78.7%-15.8pp | -62.9% | N/A |
| Current Ratio | 1.41-0.5x | 1.89-5.0x | 6.89+0.5x | 6.43+5.9x | 0.51+0.2x | 0.32-7.3x | 7.61+1.4x | 6.20 | N/A |
| Debt-to-Equity | N/A | N/A | 0.36+0.2x | 0.14 | N/A | N/A | 0.18+0.2x | 0.00 | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | -221475.7% | -8900.1% | -6184.3% | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$4.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Where Iterum Therapeutics Plc Ranks
Frequently Asked Questions
Is Iterum Therapeutics Plc profitable?
No, Iterum Therapeutics Plc (ITRMF) reported a net income of -$24.8M in fiscal year 2024.
What is Iterum Therapeutics Plc's EBITDA?
Iterum Therapeutics Plc (ITRMF) had EBITDA of -$18.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Iterum Therapeutics Plc have?
As of fiscal year 2024, Iterum Therapeutics Plc (ITRMF) had $24.1M in cash and equivalents against $31.2M in long-term debt.
What is Iterum Therapeutics Plc's free cash flow?
Iterum Therapeutics Plc (ITRMF) recorded an outflow of $26.8M in free cash flow during fiscal year 2024. This represents a 32.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Iterum Therapeutics Plc's operating cash flow?
Iterum Therapeutics Plc (ITRMF) recorded an outflow of $26.8M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are Iterum Therapeutics Plc's total assets?
Iterum Therapeutics Plc (ITRMF) had $44.6M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Iterum Therapeutics Plc's capital expenditures?
Iterum Therapeutics Plc (ITRMF) invested $2K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Iterum Therapeutics Plc spend on research and development?
Iterum Therapeutics Plc (ITRMF) invested $10.5M in research and development during fiscal year 2024.
What is Iterum Therapeutics Plc's current ratio?
Iterum Therapeutics Plc (ITRMF) had a current ratio of 1.41 as of fiscal year 2024, which is considered adequate.
What is Iterum Therapeutics Plc's return on assets (ROA)?
Iterum Therapeutics Plc (ITRMF) had a return on assets of -55.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Iterum Therapeutics Plc's cash runway?
Based on fiscal year 2024 data, Iterum Therapeutics Plc (ITRMF) had $24.1M in cash against an annual operating cash burn of $26.8M. This gives an estimated cash runway of approximately 11 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Iterum Therapeutics Plc's debt-to-equity ratio negative or not reported?
Iterum Therapeutics Plc (ITRMF) has negative shareholder equity of -$4.1M as of fiscal year 2024, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Iterum Therapeutics Plc's Piotroski F-Score?
Iterum Therapeutics Plc (ITRMF) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Iterum Therapeutics Plc's earnings high quality?
Iterum Therapeutics Plc (ITRMF) reported a net loss of $24.8M while operations used $26.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Iterum Therapeutics Plc cover its interest payments?
Iterum Therapeutics Plc (ITRMF) reported an operating loss of $18.7M against $3.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.